NEW YORK (AP) -- German drugmaker Boehringer Ingelheim said Wednesday it has filed for additional marketing approvals for its anticlotting drug Pradaxa.
The Food and Drug Administration accepted a marketing application for Pradaxa as a treatment for deep vein thrombosis and pulmonary embolism. A deep vein thrombosis is blood clot in a deep vein, usually in the leg or pelvis, that partly or completely blocks blood flow. A pulmonary embolism occurs when one of those blood clots travels to the lungs. That can create a life-threatening blockage.
Boehringer Ingelheim said there are 900,000 deep vein thrombosis and pulmonary embolism events per year in the U.S., and about a third of them result in death.
The FDA approved Pradaxa in October 2010 as a treatment for atrial fibrillation. Boehringer Ingelheim reported $796 million in worldwide sales in the first half of 2013.
- Health Care Industry
- Boehringer Ingelheim
- deep vein thrombosis
- pulmonary embolism
- Food and Drug Administration